Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Coherus BioSciences Inc
CHRS | US
1.90
USD0.02
1.06%
CHRS | US
Loading StockChartView...
About Coherus BioSciences Inc
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
16/04/2026
Close
1.90
Open
1.87
High
1.96
Low
1.85
Coherus BioSciences Inc. a biopharmaceutical company focuses on the biosimilar and immuno-oncology market primarily in the United States. The company provides UDENYCA a biosimilar to Neulasta a long-acting granulocyte-colony stimulating factor; and CIMERLI a biosimilar to Lucentis a biosimilar product interchangeable with Lucentis for the treatment of neovascular age-related macular degeneration macular edema following retinal vein occlusion diabetic macular edema diabetic retinopathy and myopic choroidal neovascularization in the United States. It also offers YUSIMRY a biosimilar to Humira for the treatment of patients with inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body including rheumatoid arthritis juvenile idiopathic arthritis psoriatic arthritis ankylosing spondylitis Crohn's disease psoriasis and ulcerative colitis. Coherus BioSciences Inc. has license agreements with Selexis SA; AbbVie Inc.; Pfizer Inc.; Bioeq AG; and Shanghai Junshi Biosciences Co. Ltd. The company was formerly known as BioGenerics Inc. and changed its name to Coherus BioSciences Inc. in April 2012. Coherus BioSciences Inc. was incorporated in 2010 and is headquartered in Redwood City California.
View LessCHRS | US
Risk
61.9
Sharpe
1.07
Luna's Score
55/100
Recommendation
Hold
Luna says (CHRS | US)
What's Working
Positive Momentum
Strength based on increasing price with high volume
Low Market Beta (-0.4 to 0.8)
Low Debt to Equity (< 0.25)
Strong Revenue Growth (> 10%)
What's not Working
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Short percentage (> 15%)
Rich in Valuation (Price to Book > 8)
Weak Operating Margin (< 10%)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
Loading RiskMeterView...
10 days
44.5%1 month
61.9%3 months
99.8%6 months
89.8%Returns
Loading ReturnMeterView...
Fundamental Ratios
PE
-
Fwd. PE
6.80
Price to book
73.19
Debt to equity
-3.55
Debt to assets
0.44
Ent. to EBITDA
16.96
Ent. to rev.
0.68
PEG
-
Other Fundamentals
EBITDA
-142.29M
MarketCap
210.29M
MarketCap(USD)
210.29M
Div. yield
-
Op. margin
-31.56
Erngs. growth
-75.50
Rev. growth
10.70
Ret. on equity
-1.66K
Short ratio
12.98
Short perc.
28.32
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Loading MovingAverageView...
Range10D
0.37
Range1M
0.44
Range3M
1.11
Volumes: Market Activity
Volume Averages
Loading VolumeAverageView...
Rel. volume
1.43
Price X volume
3.12M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 16.96 | 0.53 | Expensive |
| Ent. to Revenue | 0.68 | 3,967.00 | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 73.19 | 15.55 | Expensive |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 99.81 | 72.80 | Riskier |
| Debt to Equity | -3.55 | -1.23 | Cheaper |
| Debt to Assets | 0.44 | 0.25 | Expensive |
| Market Cap | 210.29M | 3.66B | Emerging |
